Table 4 Treatment-emergent adverse events of interest for nivolumab (100-day safety window).

Adverse events preferred term	Any grade	Grade 3/4
Diarrhoea	7 (22.6)	0
Rash	4 (12.9)	0
Hypothyroidism	4 (12.9)	0
Interstitial lung disease^a	2 (6.5)	1 (3.2)
Gamma-glutamyltransferase increased	2 (6.5)	0
Alanine aminotransferase increased	1 (3.2)	0
Aspartate aminotransferase increased	1 (3.2)	0
Blood alkaline phosphatase increased	1 (3.2)	0
Adrenal disorder	1 (3.2)	0

Data are presented as n (%) for adverse events observed between the first day of the regimen and 100 days after the last dose.
There were no Grade 5 adverse events.
^aBoth events were serious drug-related adverse events.

Quick links

Search